Injective Signs MOU with KRW1: Korean Won Settlement Layer Takes Shape—What’s Still Needed to Drive INJ Buying?

As of 02:46 Beijing time on October 21, 2026, the topic #InjectiveSignsMoUToMakeKRW1ExclusiveWonSettlementAsset ranked third on Binance Square’s trending list, with 26 discussing. Behind the buzz is a recent development: on October 20, Injective announced that it had signed an MOU with BDACS, a South Korean digital asset custodian. The plan is to use KRW1, a Korean won stablecoin issued by BDACS, as a Korean won settlement asset for RWA and tokenization use cases in the Injective ecosystem.

Bottom line: this adds a piece to Injective’s “on-chain financial infrastructure for institutions” narrative, but it cannot yet be equated with new buying demand for INJ. KRW1 serves as a Korean won-denominated asset for settlement. The announcement did not state that a trading market had gone live, that assets had already migrated, or that any settlement volume had been generated. Nor did it disclose any mechanism for INJ buybacks or revenue distribution. The key question to track is whether this MOU can evolve from a partnership into measurable on-chain usage.

Why is this worth watching? If traditional assets are tokenized for Korean institutions and settled in a KRW-denominated asset, this could theoretically reduce the friction of first converting to a USD stablecoin for every transaction. Injective describes the partnership as serving RWA and tokenized markets; BDACS’s KRW1 materials indicate that the asset was still within the scope of a PoC and compliance preparation. In other words, the direction is “bringing the Korean won into on-chain finance,” but the status remains an early-stage infrastructure partnership, not a commercially proven operation at scale.

INJ spot entry (INJ/USDT spot): https://www.binance.com/en/trade/INJ_USDT?type=spot

For INJ, the bullish thesis needs to pass through at least three stages: first, KRW1 needs clear issuance, redemption, and compliance arrangements; second, real KRW-denominated RWA issuance, trading, or settlement needs to take place on Injective; and third, these activities need to increase demand for network fees, staking, or ecosystem participation. If only the first stage is met—or if there is merely an MOU—it can usually support thematic expectations, but does not prove that value is being captured by the token.

The market action also offers no evidence that “announcement = trend reversal.” At 02:46 Beijing time, Binance spot INJ was around 8.544 USDT, down about 0.175% over 24 hours; the INJUSDT USDⓈ-M perpetual was around 8.534 USDT, down about 0.269%. The most recent completed 4-hour candlestick (20th, 20:00 to 21st, 00:00) peaked at 9.184 and closed at 8.605, with volume of about 778,600 tokens. The current price is below that candle’s close, so it remains to be seen whether buyers will step in after the spike.

INJ perpetual entry (INJUSDT USDⓈ-Margined Perpetual): https://www.binance.com/en/futures/INJUSDT

Perpetual open interest is about 3.8201 million tokens, and the latest funding rate is about -0.000819%. This only indicates that funding costs in the leveraged market currently lean slightly bearish; it cannot explain the direction on its own. If the price subsequently moves back above around 9.184, while spot trading volume increases and open interest rises without the funding rate becoming overheated, that would look more like the market continuing to price in expectations around the event. If the price remains below 8.442, or if the partnership is slow to go live and provide real settlement data, the narrative premium from the MOU could fade first.

My view is that KRW1 gives Injective a more concrete story around KRW-denominated RWA settlement, but what matters most now is verifying “usage,” not “headlines.” Readers can watch for three developments: whether a formal launch date and scope of support are announced, whether details emerge on the first tokenized assets or settlement volumes, and whether INJ network activity and demand for the token improve in tandem. Until such evidence appears, it is best viewed as an infrastructure option, not a catalyst that has already delivered cash flows.

Sources: Injective official announcement https://injective.com/vi/blog/bdacs ; BDACS KRW1 white paper https://krw1.kr/pdf/KRW1_POC_Whitepaper_BDACS_%28Kor%29.pdf ; trending topics https://www.binance.com/en/square/trends . Market data: 2026-10-21 02:46 CST, based on Binance’s public spot and USDⓈ-M perpetual endpoints; the 4-hour candlestick is the most recently completed period.

Risk warning: This article is for informational purposes only and observes the event and market structure; it does not constitute investment advice. An MOU does not mean commercial deployment, and stablecoin issuance, redemption, compliance, and liquidity may still change. Digital asset prices are volatile, and perpetual contracts also carry leverage, funding rate, and liquidation risks.

$INJ